2021 is on track to rival peak year 2018 in lobbying intensity on the 340B drug pricing program.
Attention on health care lobbying in Washington today focuses on the huge sums the drug industry is spending fighting Democratic drug price negotiation and related proposals. But off the radar, drug companies and their trade groups, health systems and their associations, insurance companies, drug distributors, group purchasing organizations, and others increasingly are lobbying about 340B.
2021 is on track to rival peak year 2018 in lobbying intensity on the 340B drug pricing program.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
×